Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Cardiovascular Medicine
Erschienen in: Current Treatment Options in Cardiovascular Medicine 9/2020

01.09.2020 | Heart Failure (W Tang, Section Editor)

Novel Devices for the Cardiorenal Syndrome in Heart Failure

verfasst von: Maria Rosa Costanzo, MD, FACC, FAHA, FESC

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Reduced responsiveness to diuretics is ubiquitous and multifactorial in heart failure and portends poor outcomes. Due to the limitations of current diuretic approaches, there is an enormous unmet clinical need for more effective fluid removal methods in heart failure patients.

Recent Findings

Novel volume management approaches include veno-venous ultrafiltration, peritoneal-based sodium and water removal methods, controlled diuresis, transvenous renal venous decongestion, catheter-deployed pumps in the descending aorta to increase renal perfusion, device-driven increase of lymphatic flow into the venous system, and catheter-based splanchnic nerve modulation.

Summary

Overall novel fluid management therapies are at an early stage of development, with some still in pre-clinical trials and others having been studied in first-in-man trials with a small number of subjects. Further investigation of novel fluid management methods should focus on assessment of safety, ease of use, candidates’ selection, reproducibility of effects across heart failure patient populations, and costs.
Literatur
1.
• ter Maaten JM, Valente MA, Damman K, et al. Diuretic response in acute heart failure—pathophysiology, evaluation, and therapy. Nat Rev Cardiol. 2015;12:184–92. Excellent review of the mechanisms of diuretic resistance in heart failure.PubMedCrossRef
2.
•• Costanzo MR, Ronco C, Abraham WT, et al. Extracorporeal ultrafiltration for fluid overload in heart failure: current status and prospects for further research. J Am Coll Cardiol. 2017;69:2428–45. State-of-the-art review of isolated veno-venous ultrafiltration with recommendations on patient selection, therapy monitoring, and adjustment in individual patients.PubMedPubMedCentralCrossRef
3.
Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail. 2014;20:392–9.PubMedPubMedCentralCrossRef
4.
Gheorghiade M, Filippatos G. Reassessing treatment of acute heart failure syndromes: the ADHERE registry. Eur Heart J Suppl. 2005;7:B13–9.CrossRef
5.
Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260–6.PubMedCrossRef
6.
Bello NA, Claggett B, Desai AS, McMurray JJV, Granger CB, Yusuf S, et al. Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. Circ Heart Fail. 2014;7(4):590–5.PubMedPubMedCentralCrossRef
7.
Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.PubMedPubMedCentralCrossRef
8.
Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE Acute Heart Failure Randomized Trial. JAMA. 2013;310:2533–43.PubMedPubMedCentralCrossRef
9.
Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296–304.PubMedPubMedCentralCrossRef
10.
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527–34.PubMedCrossRef
11.
Brisco-Bacik MA, Ter Maaten JM, Houser SR, et al. Outcomes associated with a strategy of adjuvant metolazone or high-dose loop diuretics in acute decompensated heart failure: a propensity analysis. J Am Heart Assoc. 2018;7:e009149.PubMedPubMedCentralCrossRef
12.
Cox ZL, Hung R, Lenihan DJ, Testani JM. Diuretic strategies for loop diuretic resistance in acute heart failure. The 3T trial. J Am Coll Cardiol Heart Fail. 2020;8:157–68.
13.
Konstam MA, Gheorghiade M, Burnett JC Jr, for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) investigators, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319–31.PubMedCrossRef
14.
Massie BM, O’Connor CM, Metra M, for the PROTECT investigators and committees, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 2010;363:1419–28.PubMedCrossRef
15.
O’Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure published correction appears in N. Engl J Med. 2011;365:32–43.CrossRef
16.
Ronco C, Ricci Z, Bellomo R, Bedogni F. Extracorporeal ultrafiltration for the treatment of overhydration and congestive heart failure. Cardiology. 2001;96:155–68.PubMedCrossRef
17.
Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.PubMedCrossRef
18.
Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WHW, et al. The kidney in congestive heart failure: “are natriuresis, sodium and diuretics really the good, the bad and the ugly?”. Eur J Heart Fail. 2014;16:133–42.PubMedCrossRef
19.
Grodin JL, Carter S, Bart BA, Goldsmith SR, Drazner MH, Tang WHW. Direct comparison of ultrafiltration to pharmacological decongestion in heart failure: a per-protocol analysis of CARRESS-HF. Eur J Heart Fail. 2018;20:1148–56.PubMedCrossRef
20.
Costanzo MR, Kazory A. Better late than never: the true results of CARRESS-HF. Eur J Heart Fail. 2018;20:1157–9.PubMedCrossRef
21.
Costanzo MR, Negoianu D, Fonarow GC, Jaski BE, Bart BA, Heywood JT, et al. Rationale and design of the Aquapheresis versus intravenous diuretics and hospitalization for heart failure (AVOID-HF) trial. Am Heart J. 2015;170:471–82.PubMedCrossRef
22.
Costanzo MR, Negoianu D, Jaski BE, et al. Aquapheresis versus intravenous diuretics and hospitalizations for heart failure. J Am Coll Cardiol HF. 2016;4:95–105.
23.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.PubMedCrossRef
24.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey de Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.PubMedCrossRef
25.
Schrier RW, Bansal S. Pulmonary hypertension, right ventricular failure, and kidney: different from left ventricular failure? Clin J Am Soc Nephrol. 2008;3:1232–7.PubMedPubMedCentralCrossRef
26.
Marenzi G, Muratori M, Cosentino ER, Rinaldi ER, Donghi V, Milazzo V, et al. Continuous ultrafiltration for congestive heart failure: the CUORE trial. J Card Fail. 2014;20:9–17.PubMedCrossRef
27.
28.
Biegus J, Zymlinski R, Siwolowski P, et al. Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGET-1 and TARGET-2 studies. Eur J Heart Fail. 2019;21:1079–87.PubMedCrossRef
29.
Levey AS, Inker LA. Assessment of glomerular filtration rate in health and disease: a state-of-the-art review. Clin Pharmacol Ther. 2017;102:405–19.PubMedCrossRef
30.
Bragadottir G, Redfors B, Ricksten SE. Assessing glomerular filtration rate (GFR) in critically ill patients with acute kidney injury–true GFR versus urinary creatinine clearance and estimating equations. Crit Care. 2013;17:R108.PubMedPubMedCentralCrossRef
31.
• Felker GM, Ellison DH, Mullens W, et al. Diuretic therapy for patients with heart failure. J Am Coll of Cardiol. 2020;75:1178–95. Excellent state-of-the-art review on diuretic strategies currently employed for the treatment of heart failure.CrossRef
32.
Rao VS, Turner JM, Griffin M, et al. First in human experience with peritoneal direct sodium removal using a zero sodium solution: a new candidate therapy for volume overload. Circulation. 2020;141:1043–53.PubMedCrossRefPubMedCentral
33.
Cops J, Haesen S, De Moor B, Mullens W, Hansen D. Current animal models for the study of congestion in heart failure: an overview. Heart Fail Rev. 2019;24:387–97.PubMedPubMedCentralCrossRef
34.
Kazory A, Bargman JM. Defining the role of peritoneal dialysis in management of congestive heart failure. Exp Rev Cardiovasc Ther. 2019;7:533–43.CrossRef
35.
Mahoney D, Rao V, Asher J, Struyk G, Boutagy N, Feher A, et al. Development of a direct peritoneal sodium removal technique with salt-free solution. J Cardiac Fail. 2018;24:S34.CrossRef
36.
Feld Y, Hanani H, Costanzo MR. Hydrostatic pressure gradient ultrafiltration device: a novel approach for extracellular fluid removal. J Heart Lung Transplant. 2018;37:794–6.PubMedCrossRef
37.
Shabari FR, George J, Cuchiara MP, Langsner RJ, Heuring JJ, Cohn WE, et al. Improved hemodynamics with a novel miniaturized intra-aortic axial flow pump in a porcine model of acute left ventricular dysfunction. ASAIO J. 2013;59:240–5.PubMedCrossRef
38.
Annamalai SK, Esposito ML, Reyelt LA, et al. Abdominal positioning of the next-generation intra-aortic fluid entrainment pump (Aortix) improves cardiac output in a swine model of heart failure. Circ Heart Fail. 2018;11:e005115.PubMedPubMedCentralCrossRef
39.
Vora AN, Schuiler Jones W, DeVore AD, et al. First-in-human experience with Aortix inraaortic pump. Catheter Cardiovasc Interv. 2019;93:428–33.PubMedCrossRef
40.
41.
42.
43.
Dierckx R, Vanderheyden M, Heggermont W, Goethals M, Verstreken S, Bartunek J. Treatment of diuretic resistance with a novel percutaneous blood flow regulator: concept and initial experience. J Cardiac Fail. 2019;25:932–4.CrossRef
44.
45.
Fudim M, Jones WS, Boortz-Marx RL, Ganesh A, Green CL, Hernandez AF, et al. Splanchnic nerve block for acute heart failure. Circulation. 2018;138:951–3.PubMedPubMedCentralCrossRef
46.
Fudim M, Ganesh A, Green C, Jones WS, Blazing MA, DeVore AD, et al. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. Eur Heart J. 2018;39:4255–6.PubMedPubMedCentralCrossRef
47.
Miller WL. Fluid volume overload and congestion in heart failure. Time to Reconsider Pathophysiology and How Volume Is Assessed. Circ Heart Fail. 2016;9:e002922.PubMedCrossRef
48.
Miller WL, Mullan BP. Understanding the heterogeneity in volume overload and fluid distribution in decompensated heart failure is key to optimal volume management: role for blood volume quantitation. JACC Heart Fail. 2014;2:298–305.PubMedCrossRef
49.
50.
•• Hollenberg SM, Warner Stevenson L, Ahmad T, et al. ACC expert consensus decision pathway on risk assessment, management and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll of Cardiol. 2019;74:1966–2011. Expanded focus on all aspects of acute heart failure beyond previously published guidelines recommendations.CrossRef
Metadaten
Titel
Novel Devices for the Cardiorenal Syndrome in Heart Failure
verfasst von
Maria Rosa Costanzo, MD, FACC, FAHA, FESC
Publikationsdatum
01.09.2020
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 9/2020
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-020-00823-z

Weitere Artikel der Ausgabe 9/2020

Current Treatment Options in Cardiovascular Medicine 9/2020 Zur Ausgabe

Cerebrovascular Disease and Stroke (S Silverman, Section Editor)

Current Treatment Options in Cardiovascular Medicine: Update on Reversible Cerebral Vasoconstriction Syndrome

Heart Failure (W Tang, Section Editor)

Shock Team Approaches in Managing Cardiogenic Shock—Intersection Between Critical Care and Advanced Heart Failure and Transplant Cardiology

Cerebrovascular Disease and Stroke (S Silverman, Section Editor)

Inflammatory Vasculitides of the Central Nervous System

Prevention (K Aragam, Section Editor)

A Nudge Towards Cardiovascular Health: Applications of Behavioral Economics for Primary and Secondary Cardiovascular Prevention

Heart Failure (W Tang, Section Editor)

Implementing CardioMEMS Monitoring and Interventions into Clinical Practice

Imaging (Q Truong, Section Editor)

Long-Term Prognostic Role of Computed Tomography Coronary Angiography for Stable Angina

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise